Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders



Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company focused on new technologies, including the targeting of oncological diseases, announced the results of its 2021 annual general meeting of shareholders, held on December 2, 2021 in Hong Kong.

At the annual general meeting, the required number of shareholders of the Company:

  1. Re-elected all current directors of the Company, namely Mr. Ian Huen, Mr. Darren Lui, Dr Clark Cheng, Mr. Charles Bathurst, Dr Mirko Scherer, Professor Justin Wu and Professor Douglas Arner as directors of the Company until the next annual general meeting of shareholders of the Company or until their respective successors are duly appointed and qualified;

  2. Approved, ratified and confirmed the reappointment of Marcum Bernstein & Pinchuk LLP as independent auditors of the Company for the fiscal year ending December 31, 2021 and authorized the Board of Directors to fix the remuneration of the auditors; and

  3. Approved, as a Special Resolution, an amendment to Section 49.1 and Section 49.2 of the Company’s Amended and Restated Second Memorandum and Articles of Association, which removes the requirement that the date of registration be no earlier on the date called a meeting of shareholders and instead, allows the board of directors of Aptorum more flexibility to set a date of record as deemed appropriate, in accordance with the laws of the Cayman Islands and those of the NASDAQ Global Market .

About the Aptorum group

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic actives to treat diseases with unmet medical needs, particularly in oncology (including including orphan indications in oncology) and infectious diseases. Aptorum’s pipeline is also enriched by (i) the establishment of drug discovery platforms allowing the discovery of new therapeutic actives, for example the systematic screening of existing approved drug molecules and a research platform based on the microbiome for the treatment of metabolic diseases; and (ii) the co-development of a new molecular technology for rapid diagnostic identification and detection of pathogens with Accelerate Technologies Pte Ltd, the commercialization arm of the Agency for Science, Technology and Research of Singapore.

For more information on Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and forward-looking statements

This press release does not constitute an offer to sell or a solicitation of offers to buy shares of Aptorum Group.

This press release includes statements about Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To this end, all statements contained in this document which are not statements of historical fact can be considered forward-looking statements. In some cases, you can identify forward-looking statements by words such as “may”, “should”, “expects”, “anticipates”, “anticipates”, “could”, “” contemplates “,” believes ” , “Estimate”, “predict”, “potential” or “continuing”, or the negative of these or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding expected timelines for application submissions and essays, in large part on its current expectations and projections regarding future events and trends that it believes could affect its business, its financial position and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the risks associated with its changes in advertised management and organization, continuous service and availability of key personnel. , its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks described in more detail in Aptorum Group’s Form 20-F and in other documents that the Aptorum Group may file with the SEC in the future, as well only in the prospectus which received visa n ° 20-352 from the Autorité des Marchés Financiers on July 16, 2020. Consequently, the projections included in these forward-looking statements are subject to change and actual results may differ significantly from those described here. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of Regulation (EU) n ° 2017/1129 of June 14, 2017 as amended by Delegated Regulations (EU) n ° 2019/980 of March 14, 2019 and n ° 2019/979 of March 14, 2019.

This press release is provided “as is” without any representation or warranty of any kind.


Comments are closed.